Skip to Main content Skip to Navigation
Journal articles

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study

J. Lazarovici 1, 2 P. Dartigues 1, 3 P. Brice 4 L. Oberic 5 I. Gaillard 6 M. Hunault-Berger 7, 8 F. Broussais-Guillaumot 9 E. Gyan 10 S. Bologna 11 E. Nicolas-Virelizier 12 M. Touati 13 O. Casasnovas 14 R. Delarue 15 F. Orsini-Piocelle 16 A. Stamatoullas 17 J. Gabarre 18 L.-M. Fornecker 19 T. Gastinne 20 F. Peyrade 21 V. Roland 22 E. Bachy 12 M. André 23 N. Mounier 21 C. Ferme 1 
Abstract : Nodular lymphocyte predominant Hodgkin lymphoma represents a distinct entity from classical Hodgkin lymphoma. We conducted a retrospective study to investigate the management of patients with nodular lymphocyte predominant Hodgkin lymphoma. Clinical characteristics, treatment and outcome of adult patients with nodular lymphocyte predominant Hodgkin lymphoma were collected in Lymphoma Study Association centers. Progression-free survival (PFS) and overall survival (OS) were analyzed, and the competing risks formulation of a Cox regression model was used to control the effect of risk factors on relapse or death as competing events. Among 314 evaluable patients, 82.5% had early stage nodular lymphocyte predominant Hodgkin lymphoma. Initial management consisted in watchful waiting (36.3%), radiotherapy (20.1%), rituximab (8.9%), chemotherapy or immuno-chemotherapy (21.7%), combined modality treatment (12.7%), or radiotherapy plus rituximab (0.3%). With a median follow-up of 55.8 months, the 10-year PFS and OS estimates were 44.2% and 94.9%, respectively. The 4-year PFS estimates were 79.6% after radiotherapy, 77.0% after rituximab alone, 78.8% after chemotherapy or immuno-chemotherapy, and 93.9% after combined modality treatment. For the whole population, early treatment with chemotherapy or radiotherapy, but not rituximab alone (Hazard ratio 0.695 [0.320-1.512], P=0.3593) significantly reduced the risk of progression compared to watchful waiting (HR 0.388 [0.234-0.643], P=0.0002). Early treatment appears more beneficial compared to watchful waiting in terms of progression-free survival, but has no impact on overall survival. Radiotherapy in selected early stage nodular lymphocyte predominant Hodgkin lymphoma, and combined modality treatment, chemotherapy or immuno-chemotherapy for other patients, are the main options to treat adult patients with a curative intent.
Document type :
Journal articles
Complete list of metadata

Cited literature [28 references]  Display  Hide  Download
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Tuesday, August 11, 2020 - 9:04:52 AM
Last modification on : Thursday, August 4, 2022 - 5:21:56 PM
Long-term archiving on: : Monday, November 30, 2020 - 5:33:38 PM


Publication funded by an institution



J. Lazarovici, P. Dartigues, P. Brice, L. Oberic, I. Gaillard, et al.. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. Haematologica, Ferrata Storti Foundation, 2015, 100 (12), pp.1579-1586. ⟨10.3324/haematol.2015.133025⟩. ⟨inserm-02913989⟩



Record views


Files downloads